Currently, there are 446.69M common shares owned by the public and among those 384.28M shares have been available to trade.
The company’s stock has a 5-day price change of 0.18% and 1.49% over the past three months. RPRX shares are trading 1.60% year to date (YTD), with the 12-month market performance down to -8.61% lower. It has a 12-month low price of $25.20 and touched a high of $31.66 over the same period. RPRX has an average intraday trading volume of 2.64 million shares. The stock is trading above its simple moving averages at the SMA20, SMA50, and SMA200, as the current price level is off by 4.75%, 5.40%, and 1.33% respectively.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
Institutional ownership of Royalty Pharma plc (NASDAQ: RPRX) shares accounts for 69.49% of the company’s 446.69M shares outstanding.
It has a market capitalization of $12.90B and a beta (3y monthly) value of 0.45. The stock’s trailing 12-month PE ratio is 16.02, while the earnings-per-share (ttm) stands at $1.78. The company has a PEG of 5.01 and a Quick Ratio of 12.52 with the debt-to-equity ratio at 0.94. Price movements for the stock have been influenced by the stock’s volatility, which stands at 1.54% over the week and 1.88% over the month.
Earnings per share for the fiscal year are expected to decrease by -13.85%, and 13.19% over the next financial year. EPS should grow at an annualized rate of 3.20% over the next five years, compared to 2.23% over the past 5-year period.
Looking at the support for the RPRX, a number of firms have released research notes about the stock. UBS stated their Neutral rating for the stock in a research note on June 03, 2024, with the firm’s price target at $28. UBS coverage for the Royalty Pharma plc (RPRX) stock in a research note released on June 14, 2022 offered a Buy rating with a price target of $47. Scotiabank was of a view on May 13, 2022 that the stock is Sector Outperform, while Goldman gave the stock Buy rating on April 27, 2022, issuing a price target of $56. JP Morgan on their part issued Overweight rating on April 14, 2022.
